0001193125-26-405580 Sample Contracts
7,857,143 Shares VIKING THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT September 23, 2026Underwriting Agreement • September 28th, 2026 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
The information in this pricing term sheet supplements Viking Therapeutics, Inc.’s preliminary prospectus supplement, dated September 23, 2026 (the “Common Stock Preliminary Prospectus Supplement”), relating to an offering of common stock (the “Common Stock Offering”), and Viking Therapeutics, Inc.’s preliminary prospectus supplement, dated September 23, 2026 (the “Convertible Note Preliminary Prospectus Supplement,” and, together with the Common Stock Preliminary Prospectus Supplement, the “Preliminary Prospectus Supplements”), relating to an offering of convertible senior notes due 2032 (the “Convertible Note Offering”), and supersedes the information in the applicable Preliminary Prospectus Supplement to the extent inconsistent with the information in that Preliminary Prospectus Supplement. Terms used, but not defined, in this pricing term sheet have the respective meanings set forth in the applicable Preliminary Prospectus Supplement. As used in this pricing term sheet, “we,” “our”
Viking Therapeutics, Inc. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee first SUPPLEMENTAL INDENTURE Dated as of September 25, 2026 2.00% Convertible Senior Notes due 2032First Supplemental Indenture • September 28th, 2026 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Sections 2.2 and 9.1(i) of the Base Indenture to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 2.00% Convertible Senior Notes due 2032 (the “Notes”).